Collectively, these findings demonstrate that rectal administration of ADA alleviates predominant clinical symptoms of experimental colitis in the mouse model and suppresses inflammation at the cellular level, with ADA-NP showing the highest therapeutic efficacy. The gene discussed is ADA; the disease is colitis.